RESEARCH TRIANGLE PARK, NC, August 12, 2019 -- Adhera Therapeutics, Inc. (OTCQB: ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and improve patient outcomes, has partnered with Novos Patient Solutions, LLC, increasing its patient access by 400%. As a result of the partnership, Adhera Therapeutics now has additional local distribution to support growing patient demand.

Nancy Phelan, CEO of Adhera Therapeutics commented, "Partnering with Novos is an important milestone for Adhera that will provide improved patient and customer support and a better customer experience. The partnership with Novos will also help us improve the management of our business and commercialization to accelerate sales growth and increase shareholder value."

Jennifer Hughey, President of Novos Patient Solutions commented, "We’re excited to partner with Adhera Therapeutics to support patient’s access. We look forward to working together with Adhera to meet increasing patient need for Adhera Therapeutics’ product."

About Adhera Therapeutics

Adhera Therapeutics, Inc. is a specialty pharmaceutical company leveraging technology to commercialize unique therapies and improve patient outcomes. Adhera is initially focused on commercializing its United States Food and Drug Administration approved product for the treatment of hypertension to lower blood pressure through DyrctAxess, a patient-centric treatment approach. Adhera is dedicated to identifying additional assets to expand its commercial presence. Additional information can be found at www.adherathera.com.

About Novos Patient Solutions

Novos Patient Solutions (NPS) is focused on creating solutions that can improve patient access, reduce hassle and costs for patients with solutions that can lower distribution and patient access costs. NPS is changing the way patients receive their prescriptions and clients manage their business with its extensive patient access toolkit.

Forward Looking Statements

Statements made in this news release may be forward-looking statements within the meaning of federal securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. These factors include, without limitation, those contained under the heading "Risk Factors" in the most recent filings by Adhera Therapeutics with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the fiscal year ended December 31, 2018, as well as its Quarterly Reports on Form 10-Q filed thereafter. Adhera Therapeutics assumes no obligation to update or supplement forward-looking statements because of subsequent events.

Adhera Media Contact:
Nancy R. Phelan, CEO
Adhera Therapeutics, Inc.
(919) 578-5901

or

Novos Patient Solutions Media Contact:
Wendi Taylor
Novos Patient Solution, LLC
312-810-0320
wtaylor@novosps.com